Gut bacteria cocktail tested as cancer treatment booster

NCT ID NCT03838601

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a defined mixture of live gut bacteria from a healthy donor (MET-4) is safe and can be detected in patients with advanced oropharyngeal cancer receiving standard chemoradiation. Thirty participants took the bacteria by mouth daily for up to four weeks. The main goals were to check for side effects and to see if the bacterial strains could be found in stool samples. This is an early feasibility study, not designed to measure cancer outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Microbial Ecosystem Therapeutics (MET-4) - a defined mixture of live gut bacteria from a healthy donor
What this could lead to
If successful, this could show that adding specific gut bacteria to standard cancer treatment is safe and may help understand how the microbiome affects treatment outcomes.
What could go wrong
This is a very small, early feasibility study with only 30 participants. It is designed mainly to check safety and whether the bacteria can be detected, not to prove any benefit against cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.